The Intratumoral Cancer Therapies Market is expected to show positive growth in the forecast period (2022–2032) due to the development of well-designed, randomized, controlled non-crossover trials with potential benefits. Moreover, the shortfall of approved therapy might provide suitable space for emerging therapies.

 

Key takeaways from the Intratumoral Cancer Therapies Market Report

• As per DelveInsight’s estimates, the total NMSC incident cases in the 7MM was 774,926 in 2020.
• At present, there are only three Intratumoral approved drugs namely Imlygic (Talimogene laherparepvec/T-VEC; Amgen), Hensify (NBTXR3; Nanobiotix) and Delytact (teserpaturev/G47∆; Daiichi Sankyo). Imlygic (Amgen) is the first and only FDA-approved viral therapy that is injected directly into melanoma tumors.
• The majority of the emerging therapies are working on the principle of turning “cold” tumors to “hot” and then simultaneously targeting the tumor with immune checkpoint inhibitors.
• Key Intratumoral Cancer Therapies companies include Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune/ Regeneron, Philogen, Exicure, Sirnaomics, Nanobiotix, Intensity Therapeutics, NanOlogy, Lokon Pharma, Immunicum, DNAtrix, Treovir, Idera Pharmaceuticals, Immunovative Therapies, among others.
• The Intratumoral Cancer pipeline therapies expected to get launched in the forecasted period (2021-2030) include Vidutolimod, TAVO, CAVATAK, PVSRIPO, RP1, Daromun, Cavrotolimod, Cotsiranib, Hensify, INT230-6, Delolimogene mupadenorepvec, Intuvax, Tasadenoturev, G207, Tilsotolimod, AlloStim, and others.

 

Know which therapies are expected to grab major Intratumoral Cancer Therapies Market Share @ Intratumoral Cancer Therapies Market Research Report

 

Intratumoral Cancer Therapies Overview

Over the years, the research and development in cancer have drastically increased, and patients now have several treatment options, which mainly includes chemotherapy, hormone therapy, immunotherapy, gene therapy, radiotherapy, stem cell transplant, surgery, and targeted therapy. However, there is still a segment of the cancer patient population who cannot achieve any benefit or improvement from these therapeutic options. These patients face several challenges, including the development of resistance against these therapies. While the research and development for developing treatment options to mitigate prevailing limitations are still undergoing, researchers and industries have developed a keen interest in Intratumoral therapies.

Intratumoral (intralesional) administration of immunotherapeutics is a promising way to target local tumor immunity barriers directly. Even though intratumoral therapy most often refers to direct injection into the tumors, it can also refer to any therapy provided in close anatomical proximity to a tumor with the goal of direct uptake by tumors. There are different categories of intratumoral therapies: cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, cancer gene therapy, monoclonal antibodies, and small molecules.

 

Intratumoral Cancer Therapies Indication-wise Segmentation

The Intratumoral Cancer Therapies epidemiology division provides the insights about historical and current Intratumoral Cancer Therapies patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. They are segmented into-

• Intratumoral Cancer Therapies Incident Cases of Selected Cancer Types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Colorectal Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma)
• Intratumoral Cancer Therapies Target Patient Pool of Intratumoral Therapies by Cancer Types
• Intratumoral Cancer Therapies Treated Cases by Cancer Types

 

For further information of this report to understand which factors are driving Intratumoral Cancer Therapies epidemiology trends @ Intratumoral Cancer Therapies Epidemiological Insights

 

Intratumoral Cancer Therapy Market Outlook

Intratumoral (intralesional) administration of immunotherapeutics is a promising way to target local tumor immunity barriers directly. Different categories of Intratumoral Cancer Therapies in the pipeline under investigation include oncolytic viruses, monoclonal antibodies, and small molecules, and others are being investigated.

The present Intratumoral Cancer Therapy market consists of only three approved therapies, i.e., Imlygic (Talimogene laherparepvec/T-VEC; Amgen), Delytact (teserpaturev/G47∆; Daiichi Sankyo) and Hensify (NBTXR3; Nanobiotix). The first approval for an intratumoral therapy was received in 2015, wherein the United States Food and Drug Administration (US FDA) approved Imlygic (talimogene laherparepvec; T-Vec) to treat melanoma. It is a genetically modified herpes simplex virus type 1–based oncolytic immunotherapy and is the first oncolytic virus approved by the US FDA to treat unresectable melanoma recurrent after the initial surgery. Later on in 2019, the European Union (EU) approved Hensify (NBTXR3) for the treatment of patients suffering from Soft tissue sarcoma, and recently in 2021, the Japan Ministry of Health, Labour and Welfare (MHLW) granted conditional and time-limited approval to Delytact (teserpaturev) for the treatment of malignant glioma.

 

Intratumoral Cancer Therapy Pipeline Therapies and Companies

• Vidutolimod (CMP-001): Checkmate Pharmaceuticals
• TAVO(tavokinogene telseplasmid): OncoSec Medical Incorporated
• CAVATAK (V937; CVA21): Merck & Co (Viralytics)
• PVSRIPO (PVS-RIPO): Istari Oncology
• RP1 (vusolimogene oderparepvec): Replimune/ Regeneron
• Daromun (Nidlegy): Philogen
• Cavrotolimod (AST-008): Exicure
• Cotsiranib (STP705): Sirnaomics
• Hensify (NBTXR3/ PEP503): Nanobiotix
• INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
• NanoPac (LSAM paclitaxel): NanOlogy
• Delolimogene mupadenorepvec (LOAd703): Lokon Pharma
• Intuvax (Ilixadencel): Immunicum
• Tasadenoturev (DNX-2401): DNAtrix
• G207: Treovir
• Tilsotolimod (IMO-2125): Idera Pharmaceuticals
• AlloStim: Immunovative Therapies

 

Learn more about the Intratumoral Cancer Therapies in clinical trials @ Drugs for Intratumoral Cancer Therapy Treatment

 

Intratumoral Cancer Therapies Market Dynamics

DelveInsight’s Intratumoral Cancer Therapies market analysis demonstrates that these therapies have immense potential to transform the treatment landscape by turning cold tumors into hot tumor and making their identification convenient by the immune system.  However, the present understanding of Intratumoral therapies is poor and they also have faced backlash from the recent clinical trial failures at late stages; DelveInsight estimates that the future carries a promising outlook for the Intratumor Cancer Therapies market owing to potential emerging therapies, promising clinical trial results, the influx of pharma and biotech players, better R&D, and increasing healthcare expenditure.

 

Scope of the Intratumoral Cancer Therapies Market Report

• Coverage: 7MM (the US, EU5, and Japan)
• Study Period: 2019- 2032
• Forecast Period- 2022-2032
• Key Intratumoral Cancer Therapies Companies: Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune/ Regeneron, Philogen, Exicure, Sirnaomics, Nanobiotix, Intensity Therapeutics, NanOlogy, Lokon Pharma, Immunicum, DNAtrix, Treovir, Idera Pharmaceuticals, AlloStim: Immunovative Therapies, and several others.
• Key Intratumoral Cancer Therapies in the Pipeline: Vidutolimod, Tavo, CAVATAK, PVSRIPO, RP1, Daromun, Cavrotolimod, Cotsiranib, Hensify, INT230-6, NanoPac, Delolimogene mupadenorepvec, Intuvax, Tasadenoturev, G207, Tilsotolimod, AlloStim, and several others.
• Intratumoral Cancer Therapies Market Segmentation: By Geography, By Intratumoral Cancer Therapies
• Analysis: Comparative and conjoint analysis of Intratumoral Cancer Therapies emerging therapies
• Tools used: SWOT analysis, Conjoint Analysis, Porter’s Five Forces, PESTLE analysis, BCG Matrix analysis methods.
• Case Studies
• KOL’s Views
• Analyst’s Views

 

Table of Content

1. Key Insights
2. Executive Summary of Intratumoral Cancer Therapies
3. Competitive Intelligence Analysis for Intratumoral Cancer Therapies
4. Intratumoral Cancer Therapies: Market Overview at a Glance
5. Intratumoral Cancer Therapies: Disease Background and Overview
6. Patient Journey
7. Intratumoral Cancer Therapies Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Intratumoral Cancer Therapies Unmet Needs
10. Key Endpoints of Intratumoral Cancer Therapies Treatment
11. Intratumoral Cancer Therapies Marketed Products
12. Intratumoral Cancer Therapies Emerging Therapies
13. Intratumoral Cancer Therapies: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Intratumoral Cancer Therapies Market Outlook
16. Access and Reimbursement Overview of Intratumoral Cancer Therapies
17. KOL Views
18. Intratumoral Cancer Therapies Market Drivers
19. Intratumoral Cancer Therapies Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

 

Discover more about Intratumoral Cancer Therapies Medications in development @ Intratumoral Cancer Therapies Clinical Trials

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/